Table 5.
Main characteristics and treatments of pituitary tumours in our series of MEN1 patients
| Pituitary tumours | Patients n. (%) | Clinical presentation | Surgery | Pharmacological treatment Dopamine agonist (Cabergoline) n. (%) |
|||
|---|---|---|---|---|---|---|---|
| FTs n. (%) |
NFAs n. (%) |
Combination of FTs n. (%) |
No surgery n. (%) |
Transphenoidal resection n. (%) |
|||
| Total patients with pituitary tumours | 75 (51.72)%) | 62 (42.76%) - 59 PRLomas (40.69%) - 3 corticotropinoma (2.07%) |
12 (8.28%) | 1 (0.69%) - 1 PRLoma-1 somatotropinoma (0.69%) |
64 (85.33%) | 11 (14.67%) | 30 (40%) |
| A pituitary tumour as first clinical manifestation | 25 (17.24%) | 25 (17.24%) - 24 PRLomas (16.55%) - 1 corticotropinoma (0,69%) |
0 | 0 | 18 (24%) | 7 (9.33%) | 10 (13.33%) |
| Index cases (probands) | 54 (37.24%) | 44 (30.34%) - 41 PRLomas (28.28%) - 3 corticotropinoma (2.07%) |
9 (6.21%) | 1 (0.69%) - 1 PRLoma-1 somatotropinoma (0.69%) |
44 (58.67%) | 10 (13.33%) | 17 (22.67%) |
| Relatives | 21 (14.48%) | 18 (12.41%) - 18 PRLomas (12.41%) |
3 (2.07% | 0 | 20 (26.67%) | 1 (1.33%) | 13 (17.33%) |
Footnotes: FTs Functioning tumours, NFAs non-functioning adenomas, PRLoma Prolactinoma
Percentages of clinical presentation were calculated with respect to MEN1 clinically affected patients (145). Percentages of surgery and pharmacological treatment were calculated with respect to pituitary adenoma affected patients (75)